Role of glycosylation in enveloped virus infection

doi:10.3877/cma.j.issn.1674-1358.2021.01.001

Abstract

Abstract:

During the infection process, the enveloped virus hijacked the glycosylation system of the host cell to modify its own antigen, and escape from the immune monitoring of the host. Moreover, the glycosylation modification to the envelope protein, which played the antigen shielding effect, made the development of vaccine more difficult. On the other hand, the structure of the modified polysaccharide against the major epitope also had a spatial reconstruction effect. Therefore, the construction of neutralizing antibodies to the enveloped virus was related to the structure of the modified glycan. In addition, the glycosylation modification of antigen proteins was also associated with virus recognition, adhesion, tissue tropism, quality control of viral particle assembly, toxicity and infectivity. The current advances in this field were reviewed in this article.

Key words: Virus, Antigen, Glycosylation, Glycoform, Glycan-shielding

Lingling He, Cheng Zhang, Rongrong Zhou, Hongshan Wei. Role of glycosylation in enveloped virus infection[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2021, 15(01): 1-6.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2021.01.001

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2021/V15/I01/1

References 66

[56]	Yin Y, Yu S, Sun Y, et al. Glycosylation deletion of hemagglutinin head in the H5 subtype avian influenza virus enhances its virulence in mammals by inducing endoplasmic reticulum stress[J]. Transbound Emerg Dis,2020;67(4):1492-1506.
[57]	Kim NY, Jung WW, Oh YK, et al. Natural protection from zoonosis by alpha-gal epitopes on virus particles in xenotransmission[J]. Xenotransplantation,2007,14(2):104-111.
[58]	Antonopoulos A, North SJ, Haslam SM, et al. Glycosylation of mouse and human immune cells: insights emerging from N-glycomics analyses[J]. Biochem Soc Trans,2011,39(5):1334-1340.
[59]	Whiteman MC, Li L, Wicker JA, et al. Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus[J]. Vaccine,2010,28(4): 1075-1083.
[60]	Galili U. Natural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics?[J]. Glycobiology, 2016,26(11):1140-1150.
[61]	Neil SJ, McKnight A, Gustafsson K, et al. HIV-1 incorporates ABO histo-blood group antigens that sensitize virions to complement-mediated inactivation[J]. Blood,2005,105(12):4693-4699.
[62]	Bagdonaite I, Wandall HH. Global aspects of viral glycosylation[J]. Glycobiology,2018,28(7):443-467.
[63]	Wang W, Nie J, Prochnow C, et al. A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization[J]. Retrovirology,2013,10(1):1-28.
[64]	Iraqi M, Edri A, Greenshpan Y, et al. N-Glycans Mediate the Ebola Virus-GP1 Shielding of Ligands to Immune Receptors and Immune Evasion[J]. Front Cell Infect Microbiol,2020,10(1):1-11.
[65]	Henderson EA, Tam CC, Cheng LW, et al. Investigation of the immunogenicity of Zika glycan loop[J]. Virol J,2020,17(1):1-15.
[66]	Moratorio G, Vignuzzi M. Monitoring and redirecting virus evolution[J]. PLoS Pathog,2018,14(6):e1006979.
[1]	Bouwman Tokatlian T, Read BJ, Jones CA, et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers[J]. Science,2019,363(6427):649-654.
[2]	Bayer K, Banning C, Bruss V, et al. Hepatitis C virus is released via a noncanonical secretory route[J]. J Virol,2016,90(23):10558-10573.
[3]	Luther KB, Hülsmeier AJ, Schegg B, et al. Mimivirus collagen is modified by bifunctional lysyl hydroxylase and glycosyltransferase enzyme[J]. J Biol Chem,2011,286(51):43701-43709.
[4]	Xiang Y, Baxa U, Zhang Y, et al. Crystal structure of a virus-encoded putative glycosyltransferase[J]. J Virol,2010,84(23):12265-12273.
[5]	Kumar S, Maurya VK, Prasad AK, et al. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)[J]. Virusdisease,2020,31(1):13-21.
[6]	An Y, McCullers JA, Alymova I, et al. Glycosylation analysis of engineered H3N2 influenza A virus hemagglutinins with sequentially added historically relevant glycosylation sites[J]. J Proteome Res,2015,14(9):3957-3969.
[7]	Huang Y, Owino SO, Crevar CJ, et al. N-linked glycans and K147 residue on hemagglutinin synergize to elicit broadly reactive H1N1 influenza virus antibodies[J]. J Virol,2020,94(6):e01432-19.
[8]	Wu NC, Wilson IA. A Perspective on the structural and functional constraints for immune evasion: insights from influenza virus[J]. J Mol Biol,2017,429(17):2694-2709.
[9]	Rouvinski A, Dejnirattisai W, Guardado-Calvo P, et al. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope[J]. Nat Commun,2017,8(1):1-12.
[10]	Igarashi M, Ito K, Kida H, et al. Genetically destined potentials for N-linked glycosylation of influenza virus hemagglutinin[J]. Virology,376(2008):323-329.
[11]	Shao T, Pan J, Zhang S, et al. Application of MCMC-based bayesian modeling for genetic evolutionary and dynamic change analysis of Zika virus[J]. Front Genet,2020,10(1):1-9.
[12]	Yin Y, Yu S, Sun Y, et al. Glycosylation deletion of hemagglutinin head in the H5 subtype avian influenza virus enhances its virulence in mammals by inducing endoplasmic reticulum stress[J]. Transbound Emerg Dis,2020,67(4):1492-1506.
[13]	Manning JT, Yun NE, Seregin AV, et al. The glycoprotein of the live-attenuated Junin virus vaccine strain induces ER stress and forms aggregates prior to degradation in the lysosome[J]. J Virol,2020,94(8):e01693-19.
[14]	Liang JJ, Chou MW, Lin YL. DC-SIGN binding contributed by an extra N-linked glycosylation on Japanese encephalitis virus envelope protein reduces the ability of viral brain invasion[J]. Front Cell Infect Microbiol,2018,8(1):1-9.
[15]	Yan D, Shi Y, Wang H, et al. A single mutation at position 156 in the envelope protein of tembusu virus is responsible for virus tissue tropism and transmissibility in ducks[J]. J Virol,2018,92(17):e00427-18.
[16]	Boyoglu-Barnum S, Hutchinson GB, Boyington JC, et al. Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responses[J]. Nat Commun,2020,11(1):1-12.
[17]	Salpini R, Piermatteo L, Battisti A, et al. A hyper-glycosylation of HBV surface antigen correlates with HBsAg-negativity at immunosuppression-driven HBV reactivation in vivo and hinders HBsAg recognition in vitro[J]. Viruses,2020,12(2):E251.
[18]	Biering SB, Huang A, Vu AT, et al. N-Glycans on the Nipah virus attachment glycoprotein modulate fusion and viral entry as they protect against antibody neutralization[J]. J Virol,2012,86(22):11991-2002.
[19]	Cook JD, Lee JE. The secret life of viral entry glycoproteins: moonlighting in immune evasion[J]. PLoS Pathog,2013,9(5): e1003258.
[20]	Hastie KM, Zandonatti MA, Kleinfelter LM, et al. Structural basis for antibody-mediated neutralization of Lassa virus[J]. Science,2017,356(6341):923-928.
[21]	Thiemmeca S, Tamdet C, Punyadee N, et al. Secreted NS1 protects dengue virus from mannose-binding lectin-mediated neutralization[J]. J Immunol,2016,197(10):4053-4065.
[22]	Hoebe EK, Le Large TY, Tarbouriech N, et al. Epstein-Barr virus-encoded BARF1 protein is a decoy receptor for macrophage colony stimulating factor and interferes with macrophage differentiation and activation[J]. Viral Immunol,2012,25(6):461-470.
[23]	Ressing ME, van Leeuwen D, Verreck FA, et al. Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class Ⅱ immune evasion[J]. J Virol,2005,79(2):841-852.
[24]	Colgrave ML, Snelling HJ, Shiell BJ, et al. Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus[J]. Glycobiology, 2012,22(4):572-584.
[25]	Hsieh P, Rosner MR, Robbins PW. Host-dependent variation of asparagine-linked oligosaccharides at individual glycosylation sites of Sindbis virus glycoproteins[J]. J Biol Chem,1983,258(4):2548-2554.
[26]	Watanabe Y, Bowden TA, Wilson IA, et al. Exploitation of glycosylation in enveloped virus pathobiology[J]. Biochim Biophys Acta Gen Subj,2019,1863(10):1480-1497.
[27]	Go EP, Ding H, Zhang S, et al. Glycosylation benchmark profile for HIV-1 envelope glycoprotein production based on eleven env trimers[J]. J Virol,2017,91(9): e02428-16.
[28]	Parsons LM, An Y, Qi L, et al. Influenza virus hemagglutinins H2, H5, H6, and H11 are not targets of pulmonary surfactant protein D: N-glycan subtypes in host-pathogen interactions[J]. J Virol,2020,94(5):e01951-19.
[29]	Zhang S, Sherwood RW, Yang Y, et al. Comparative characterization of the glycosylation profiles of an influenza hemagglutinin produced in plant and insect hosts[J]. Proteomics,2012,12(8):1269-1288.
[30]	Carbaugh DL, Lazear HM. Flavivirus envelope protein glycosylation: impacts on viral infection and pathogenesis[J]. J Virol,2020,94(11):e00104-20.
[31]	Hacker K, White L, de Silva AM. N-linked glycans on dengue viruses grown in mammalian and insect cells[J]. J Gen Virol,2009,90(9):2097-2106.
[32]	Bonomelli C, Doores KJ, Dunlop DC, et al. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade[J]. PLoS One,2011,6(8):e23521.
[33]	Wang S, Voronin Y, Zhao P, et al. Glycan profiles of gp120 protein vaccines from four major HIV-1 subtypes produced from different host cell lines under non-GMP or GMP conditions[J]. J Virol,2020,94(7):e01968-19.
[34]	Yang YR, McCoy LE, van Gils MJ, et al. Autologous neutralizing antibody responses to an HIV envelope glycan hole are not easily broadened in rabbits[J]. J Virol,2020,94(7):e01861-19.
[35]	Seabright GE, Doores KJ, Burton DR, et al. Protein and glycan mimicry in HIV vaccine design[J]. J Mol Biol,2019,431(12):2223-2247.
[36]	Feinberg H, Mitchell DA, Drickamer K, et al. Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR[J]. Science,2001,294(5549):2163-2166.
[37]	Wasik BR, Barnard KN, Parrish CR. Effects of sialic acid modifications on virus binding and infection[J]. Trends Microbiol,2016,24(12):991-1001.
[38]	Langereis MA, Bakkers MJ, Deng L, et al. Complexity and diversity of the mammalian sialome revealed by nidovirus virolectins[J]. Cell Rep,2015,11(12):1966-1978.
[39]	Vimr ER. Unified theory of bacterial sialometabolism: how and why bacteria metabolize host sialic acids[J]. ISRN Microbiol,2013,2013(1):1-26.
[40]	Anand SP, Finzi A. Understudied factors influencing Fc-mediated immune responses against viral infections[J]. Vaccines (Basel),2019,7(3):1-14.
[41]	Pritchard LK, Harvey DJ, Bonomelli C, et al. Cell- and protein-directed glycosylation of native cleaved HIV-1 envelope[J]. J Virol,2015,89(17):8932-8944.
[42]	Stencel-Baerenwald JE, Reiss K, Reiter DM, et al. The sweet spot: defining virus-sialic acid interactions[J]. Nat Rev Microbiol,2014,12(11):739-749.
[43]	Bouwman KM, Habraeken N, Laconi A, et al. N-glycosylation of infectious bronchitis virus M41 spike determines receptor specificity[J]. J Gen Virol,2020,101(6):599-608.
[44]	Baum LG, Paulson JC. Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity[J]. Acta Histochem Suppl,1990,40(1):35-38.
[45]	Van Breedam W, Pöhlmann S, Favoreel HW, et al. Bitter-sweet symphony: glycan-lectin interactions in virus biology[J]. FEMS Microbiol Rev,2014,38(4):598-632.
[46]	Shida H, Dales S. Biogenesis of vaccinia: carbohydrate of the hemagglutinin molecules[J]. Virology,1981,111(1):56-72.
[47]	Silver ZA, Antonopoulos A, Haslam SM, et al. Discovery of O-linked carbohydrate on HIV-1 envelope and its role in shielding against one category of broadly neutralizing antibodies[J]. Cell Rep,2020,30(6):1862-1869.
[48]	Bräutigam J, Scheidig AJ, Egge-Jacobsen W. Mass spectrometric analysis of hepatitis C viral envelope protein E2 reveals extended microheterogeneity of mucin-type O-linked glycosylation[J]. Glycobiology,2013,23(4):453-474.
[49]	Bagdonaite I, Nordén R, Joshi HJ, et al. Global Mapping of O-glycosylation of varicella zoster virus, human cytomegalovirus, and Epstein-Barr virus[J]. J Biol Chem,2016,291(23):12014-12028.
[50]	Martinez O, Tantral L, Mulherkar N, et al. Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles[J]. J Infect Dis,2011,204(Suppl 3):S825-S832.
[51]	Nordén R, Halim A, Nyström K, et al. O-linked glycosylation of the mucin domain of the herpes simplex virus type 1-specific glycoprotein gC-1 is temporally regulated in a seed-and-spread manner[J]. J Biol Chem,2015,290(8):5078-5091.
[52]	McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins[J]. Curr Top Microbiol Immunol,2013,372(1):83-104.
[53]	Schmitt S, Glebe D, Alving K, et al. Analysis of the pre-S2 N- and O-linked glycans of the M surface protein from human hepatitis B virus[J]. J Biol Chem,1999,274(17):11945-11957.
[54]	Midulla F, Di Mattia G, Nenna R, et al. Novel variants of respiratory syncytial virus A ON1 associated with increased clinical severity of bronchiolitis[J]. J Infect Dis,2020,222(1):102-110.
[55]	Noyori O, Matsuno K, Kajihara M, et al. Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses[J]. Virology,2013,446(1-2):152-161.

Please choose a citation manager

Content to export